Drug Profile
Zonisamide - Eisai Co Ltd
Alternative Names: AD-810; AD-810N; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; ZonegranLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Concordia Pharmaceuticals; Eisai Co Ltd; Sumitomo Pharma; Washington University School of Medicine
- Class Antidementias; Antiepileptic drugs; Antiparkinsonians; Benzoxazoles; Small molecules; Sulfonamides
- Mechanism of Action Antioxidants; Calcium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Epilepsy; Parkinson's disease
- Registered Lewy body disease
- Phase II Hearing loss
- Discontinued Cerebral ischaemia; Manic episodes; Migraine; Neuropathic pain; Obesity
Most Recent Events
- 06 Oct 2023 Washington University School of Medicine and Gateway Biotechnology terminates a phase-II trial in Hearing loss (In volunteers) in USA (PO) due to the reason that PINIHL Program terminated by DoD (NCT04768569)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 04 Oct 2021 Phase-II clinical trials in Hearing loss (In volunteers) in USA (PO) (NCT04768569)